AusBiz | Dr James Campbell
0
It was encouraging to see the market respond positively to Patrys’ (ASX:PAB) announcement of its preclinical study highlighting the potential…
Patrys demonstrates potential for deoxmabs in antibody drug conjugates (ADCs)
Today Patrys announced new data from a successful preclinical study highlighting the potential for using our deoxymab antibodies as targeting…
Bioshares | August 2021
Patrys has been featured in the latest edition of investor newsletter Bioshares. Bioshares has previously focused on the unmet needs…
Patrys FY21 Annual Report
Patrys has today released its Annual Report for the 2020-2021 Financial Year (FY21). Highlights include: 2020 Expansion of deoxymab portfolio…
QUARTERLY ACTIVITIES REPORT & 4C
Patrys has today released its Quarterly Activities Report and 4C for the quarter ended 30 June 2021. Our R&D program…
PAT-DX1 Significantly Improves Survival in Animal Model of Pancreatic Cancer
New preclinical data from the Garvan Institute of Medical Research has shown that Patrys’ deoxymab antibody PAT-DX1 is able to…
New data shows PAT-DX3 able to cross the blood brain barrier
In an exciting development, Patrys today announced new data confirming its full-sized IgG deoxymab antibody, PAT-DX3, is able to cross…
Bioshares | June 2021
Patrys has been featured in the latest edition (Edition 896) of investor newsletter Bioshares. The article highlights our Company’s strong…
Stockhead V-Con Biotechs
Patrys is delighted to be participating in the V-Con Biotechs conference this week. Presented by Stockhead, V-Con is an opportunity…
180 Markets Interview
Patrys CEO and MD, Dr James Campbell, was recently interviewed by 180 Markets CEO and Co-Founder, Greg Lowe, to summarise…